TY - JOUR
T1 - Serotonin dysregulation in adolescents with major depression
T2 - Hormone response to meta-chlorophenylpiperazine (mCPP) infusion
AU - Ghaziuddin, Neera
AU - King, Cheryl A.
AU - Welch, Kathleen B.
AU - Zaccagnini, Joan
AU - Weidmer-Mikhail, E.
AU - Mellow, Alan M.
AU - Ghaziuddin, Mohammad
AU - Greden, John F.
N1 - Funding Information:
The authors acknowledge the helpful comments of Jeffrey Halperin, Ph.D., Queen’s College, NY, and Penelope Knapp, M.D, University of California, Davis. Support for the study was provided by the GCRC, University of Michigan, Ann Arbor; and the NARSAD foundation.
PY - 2000/7/11
Y1 - 2000/7/11
N2 - This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.
AB - This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.
KW - Adolescent depression
KW - Meta- Chlorophenylpiperazine
KW - Neuroendocrine
KW - Serotonin
UR - http://www.scopus.com/inward/record.url?scp=0034636690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034636690&partnerID=8YFLogxK
U2 - 10.1016/S0165-1781(00)00163-3
DO - 10.1016/S0165-1781(00)00163-3
M3 - Article
C2 - 10974357
AN - SCOPUS:0034636690
SN - 0165-1781
VL - 95
SP - 183
EP - 194
JO - Psychiatry research
JF - Psychiatry research
IS - 3
ER -